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Background: COPD is characterized by considerable diversity in terms of clinical signs and symptoms,
physiopathological mechanisms, response to treatment and disease progression. For this reason, the identification
of different patient subgroups (or possible phenotypes) is important both for prognosis and for therapeutic
objectives. Based on the foregoing, AIMAR has decided to conduct a survey on the perception of the prevalence of
the different clinical COPD phenotypes/subtypes in the clinical practice of physicians who treat patients with
chronic obstructive pulmonary disease, and on their therapeutic objectives.
Methods: The survey consisted of 19 multiple-choice questions, compiled through a form published online. All the
data and answers entered into the system were checked for consistency and completeness directly online at the
time they were entered, and each respondent could only complete the questionnaire once.
Results: The survey took place from May through October 2012. A total of 1,434 questionnaires (60% of the sample
approached) were eligible for analysis, broken down as follows: 537 pulmonologists, 666 general practitioners (GPs),
72 internal medicine specialists, 36 allergists, 30 geriatricians, 93 other specialists. The results show that a significant
proportion of GPs (33%) identified more than 50 patients in their practices with a diagnosis of COPD. Although
most patients are or have been in treatment with a long-acting bronchodilator, the most common reasons for
seeing a GP or a specialist were exacerbations and worsening of the symptoms, suggesting the importance of
an appropriate background therapy in order to reduce the risk of disease instability. The frequent exacerbator
phenotype was the most commonly found phenotype in clinical practice (by 75% of specialists and 66% of
GPs); patients with a prevalent phenotype of chronic bronchitis were reported more often by GPs, while specialists
reported a higher number of patients with a prevalent phenotype of emphysema.
A medical history of exacerbations and the extent of deterioration of the spirometry parameters were considered to be
the major indicators for COPD severity and clinical risk. In managing the frequent exacerbator phenotype, the
therapeutic objectives – both for GPs and for specialists – included reducing airway inflammation, improving bronchial
dilation, and reducing pulmonary hyperinflation. For this type of patients at high clinical risk, specialists selected a
first-line therapeutic option based on a predetermined combination of an inhaled corticosteroid (ICS) and a
long-acting β2-agonist bronchodilator (LABA) and a second-line three-drug therapy (combination of ICS and
two long-acting bronchodilators), while GPs’ choices are more diversified, without a clear-cut prevalence of one
type of treatment. In patients with COPD and concomitant cardiovascular diseases, frequently observed in clinical
practice by all physicians, the combination of ICS and LABA was considered the first-choice option by the highest
proportion of GPs (43%) and specialists (37%), while a smaller number of specialists (35%) opted for the long
acting muscarinic antagonists (LAMA). Both GPs and specialists believe that therapeutic continuity is of primary
importance for the achievement of clinical outcomes with all classes of drugs.
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Conclusions: A good knowledge of COPD has been observed in a high percentage of GPs, indicating an
increased awareness of this disease in Primary Health Care. The frequent exacerbator phenotype is viewed by all
physicians as the most prevalent in clinical practice, bearing a high risk of hospitalization. For specialists,
therapeutic measures aimed at reducing the number and severity of exacerbations are primarily based on the
combination of inhaled corticosteroid and bronchodilator, presumably because of the complementary
pharmacological action of its components, whereas while GPs’ choices tend to be more diversified. Adherence
to medication regimens is of the essence for the achievement of clinical outcomes.
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Chronic obstructive pulmonary disease (COPD) is a com-
plex, multi-component disease with a significant heterogen-
eity with respect to clinical presentation (symptoms, exercise
tolerance, exacerbation susceptibility), radiological features,
mechanisms of airflow limitation and disease progression, in-
dependently of the degree of airflow limitation [1].
Within the scientific community there has been a
growing interest in categorizing this clinical and phys-
iopathological heterogeneity into COPD “phenotypes”.
The concept of phenotype is not new: in the mid-20th
century COPD was classified as “phenotype A”, charac-
terized by findings of emphysema, and “phenotype B”,
characterized by chronic bronchitis, on the basis of
clinical, radiological and physiopathological evidence
[2]. These two types were the extremes of a spectrum
and often coexist to different extent in most patients.
In recent years the advances of imaging diagnostics
(high resolution computerized tomography, MRI) have
considerably fostered a renewed interest in the classifi-
cation of patients by clinical-pathological phenotypes,
which is driven by the development of new studies to
define the clinical phenotypes of COPD [3-7].
An essential contribution to knowledge in this field
came from the study of the ECLIPSE [7] cohort, one of
the largest and best characterized within the scope of
COPD studies: 2,180 patients and 566 controls, smokers
and non-smokers, were followed up for three years in
order to define clinically relevant COPD subtypes and to
identify parameters and bio-markers able to predict dis-
ease progression. One of the first analyses [8] of the lon-
gitudinal data gathered from the ECLIPSE cohort led to
the identification of a distinct COPD phenotype at higher
risk of exacerbation (“frequent exacerbator”), which is
stable over time, similar across GOLD stages, character-
ized by inherent susceptibility to triggers like viral infec-
tions, clinically predictable and identifiable through the
clinical history. In fact, a medical history of exacerbations
was found to be the predictive factor most closely corre-
lated with their frequency.
More recently, it has been observed that the patient
subgroup accounting for approximately 16% of the cohorthad constantly elevated levels of markers of systemic in-
flammation, correlated with an increased risk of death and
exacerbation compared to patients with less inflammation.
It has been suggested that the constant presence of
systemic inflammation, flared up by repeated exacerba-
tions [9], identifies a new, distinct phenotype of COPD
patient, who might be treated with specific therapeutic
strategies [10].
The heterogeneity of COPD may make this disease
very complex to manage, as the different phenotypes
could have diverging prognosis or treatment needs.
Hence the interest in investigating the perception and
impact of the different COPD phenotypes in the clinical
practice of physicians who treat patients with chronic
obstructive pulmonary disease. On this basis, AIMAR
(Interdisciplinary Scientific Association for the Study of
Respiratory Diseases) decided to launch a survey on this
specific subject, with the help of an unconditional con-
tribution from GlaxoSmithKline, in order to collect in-
formation on the following main aspects:
– Perception of the frequency of the different COPD
phenotypes (frequent exacerbator, with prevalent
emphysema, with prevalent chronic bronchitis, with
marked reversibility).
– Management of the different types of COPD
patients.
Methods
On the basis of the objectives indicated above, the scien-
tific committee that thought of the survey developed a
questionnaire that acquired data through a form avail-
able online, which the respondents could complete at
any time. The questionnaire included 19 multiple-choice
questions and was addressed to the following specialists:
pulmonologists, allergy specialists, geriatricians, internal
medicine specialists and general practitioners. All the
data and answers entered into the system were checked
for consistency and completeness directly online at the
time they were entered, and each respondent could only
complete the questionnaire once. The data gathered in

























Figure 1 Number of patients with a COPD diagnosis out of
those treated by GPs.
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and therefore were immediately available for queries
even while the survey was still ongoing. The access to
the data, mediated by a back office query and reporting
system, allowed constant monitoring of the correct con-
duct of the survey; it was also possible to extract and
check data on smaller data sets.Results
Of the 1,516 questionnaires collected (corresponding to
63,4% responders), 82 were incomplete or erroneously
compiled, and therefore considered not valid, coming to a
total of 1,434 questionnaires eligible for analysis (60% of
the sample approached), broken down as follows: 537 pul-
monologists, 666 general practitioners, 72 internal medi-
cine specialists, 36 allergy specialists, 30 geriatricians, 93
other specialists (including anesthesiologists and resuscita-


















































Figure 2 Average number of patients per week (A) and average numspecialists, emergency physicians, physiatrists, oncologists,
and thoracic surgeons).Epidemiology
Against this backdrop, the results of the survey (Figure 1)
indicate that approximately one third of GPs has identi-
fied more than 50 patients in their practices with a diag-
nosis of COPD, and 56% has identified more than 20
patients: this points to an increased awareness of this
disease in Primary Health Care.
The average number of patients with COPD examined
by the majority of GPs per week is lower than 10, in line
with the stated number of patients, while specialists
range between fewer than 10 (30%), 10 to 20 (28.5%)
and more than 21 (22%) patients per week (Figure 2A).
Out of 237 specialists who declared they see fewer than
10 patients per week with COPD, 40.5% (96) are pulmo-
nologists; out of 219 specialists who said they see 10 to
20 patients, 72.6% (159) are pulmonologists; of those
who said they see more than 21 patients, 52.5% (282) are
pulmonologists.
As to the number of visits of individual patients per
year, the results show a rather high frequency – at least
three visits per year – for 85% of GPs (more than three
visits per year in 60% of cases): the reasons of the physical
examinations presumably range from disease monitoring
to worsening of the symptoms or management of possible
comorbidities. The majority of specialists see the same pa-
tient two or three times per year (Figure 2B).
Table 1 shows that the reason for not yet diagnosed
patients to first see their GP is, in 48% of cases, symp-
toms of chronic bronchitis and in 15.7% of cases an ex-



















Average number of visits per year
ber of visits on the same patient per year (B).
Table 1 Most frequent cause for patients to first see their GP or a specialist
Dyspnea & limitations Exacerbations Chronic bronchitis/cough Disease other than COPD Other
GP (%) Spec.(%) GP (%) Spec (%) GP (%) Spec. (%) GP (%) Spec. (%) GP (%) Spec. (%)
0.45 5,8 15.7 19,5 48,2 21,8 4,9 1,5 30,6 51,1
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polyglobulia secondary to the respiratory disease, in-
creased hematocrit, and symptoms of viscosity). In the
case of specialists, the main cause for first presenting for
examination is not a worsening of the symptoms or dis-
eases other than COPD, but other reasons (51%), probably
in connection with hospitalizations due to respiratory
failure [9].
As shown in Figure 3, a vast majority of patients is or
has been in treatment with a long-acting bronchodilator,
which is the first step in the treatment process in the
presence of persistent symptoms: in the event of unsatis-
factory response to the therapy, worsening of the symp-
toms and/or exacerbations, the indications might exist
for switching to a combination therapy by adding an ICS
to the long-acting β2−agonist bronchodilator (LABA).
Within this context, the survey identified exacerba-
tions and worsening of the symptoms as the most fre-
quent causes of subsequent medical examinations, both
for GPs (56% to 33% respectively) and for specialists
(37% and 40% respectively) (Figure 4).
Types of COPD patients or phenotypes
As to the heterogeneity of COPD, virtually all physicians,
whether GPs (84%) or specialists (92%), believe that
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Figure 3 Patients with COPD treated currently or in the past with lonshows the types of COPD patients most frequently en-
countered in the clinical practice of the physicians par-
ticipating in the survey: 66% of GPs report a high
incidence of the frequent exacerbator phenotype (2 o
more exacerbations per year, defined along the GOLD
2011 criteria) and of the phenotype characterized by
prevalence of chronic bronchitis; on the other hand,
among specialists the frequent exacerbator is found to
be the most common phenotype by 75%, and the pheno-
type characterized by prevalence of emphysema by 46%.
The type of patients with significant reversibility in the
bronchodilation test is encountered rarely, not only by
GPs, but also by specialists.
As to the reported prevalence of the different pheno-
types in everyday clinical practice, Table 2 shows that
the “frequent exacerbator” is perceived as having a ra-
ther high prevalence and accounts for over 30% of the
population of COPD patients according to 31% of GPs
and 45% to specialists, and for 10 to 30% according to
44% of GPs and 41% of specialists. The “chronic bron-
chitis” phenotype is also considered to have high preva-
lence, accounting for more than 30% of the COPD
patient population seen in clinical practice according to
more than half (53%) of both GPs and specialists. Con-
versely, the emphysematous is considered to have low









































Figure 4 Causes for COPD patients to submit to subsequent examinations.
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ranges between 10 and 30%. The majority of both GPs
and specialists indicates the percentage of patients with
significant reversibility as less than 10%.
Categorization of COPD patients: severity indicators, risk
of hospitalization
With regard to the key indicators for COPD patient se-
verity classification, nearly all the specialists (81%) men-
tioned a medical history of exacerbations, followed by
spirometry parameters (68%), dyspnea and low tolerance
to effort; for GPs, spirometry parameters (51%) and a
history of exacerbations (47%) are the top indicators




















Figure 5 Types of patients most frequently seen by GPs and specialisclinical history of exacerbations as the predictive factor
most closely correlated with their frequency (Figure 7).
As COPD exacerbations are crucial in this disorder
(not only do they impact significantly the patient’s qual-
ity of life and evolution of the disease, but they can also
be associated with cardiovascular complications and
death [11-16], causing a substantial increase in health
care costs [17]), we investigated how the different phe-
notypes are viewed in terms of risk of hospitalization.
Table 3 shows that the frequent exacerbator phenotype
is considered as the one at highest risk by most clini-
cians (76% of specialists and 53% of GPs), unlike the
phenotype with significant reversibility in the broncho-











ts in clinical practice.










Prevalence GP (%) Spec. (%) GP (%) Spec. (%) GP (%) Spec. (%) GP (%) Spec.(%)
<10% 23,8 13,2 60,3 31,6 13,5 13,2 65,3 69,5
10-30% 44,6 41,4 33,7 54,3 32,8 33,2 25,6 27
<30% 31,5 45,1 5,3 14 53,8 53,5 9 3,5
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that with prevalence of chronic bronchitis, the risk level
is considered medium by the majority of physicians.
Another important aspect in assessing the COPD pa-
tients’ clinical picture is the presence of comorbidities,
particularly of a cardiovascular nature, widely recognized
both by GPs and by specialists (data not shown).
The therapeutic approach: objectives and classes of drugs
While recognizing the existence of different COPD pa-
tient types or phenotypes, approximately one half of the
physicians (55% of GPs and 48% of specialists) believe
that there is a standard pharmacological approach that is
effective for all patients, i.e. the combination of inhaled
corticosteroid (ICS) and bronchodilator. This is consid-
ered by both specialists and GPs the most effective treat-
ment, followed by a combination of two bronchodilators
according to specialists, and a single bronchodilator ac-
cording to GPs (Figure 8).
If we now focus on the treatment of frequent exacer-
bators, the physiopathological mechanisms considered
by both GPs and specialists to be important in achieving
the therapeutic effect are reduction of the airways in-
flammation, increased bronchodilation, and reduction of
pulmonary hyperinflation, which is responsible for low
tolerance to physical effort (Figure 9A). Consistently
with the above, 44% of specialists indicate as first-choice





























Figure 6 Indicators for COPD severity classification.complementary action on the different physiopathologi-
cal components (inflammation and bronchial obstruc-
tion), and 40% of them favor the three-drug therapy
consisting of a combination of two bronchodilators plus
ICS (Figure 9B). Therefore, for this type of patients at
high clinical risk of exacerbations most specialists rec-
ommend the additional benefit of an ICS as opposed to
bronchodilator therapy alone, in line with the evidence
reported in literature [18-24] and incorporated in the
guidelines [1,25].
The therapeutic choices of GPs are more diversified,
although a higher proportion favors an ICS containing
regimen (35% opt for the ICS + LABA combination, 21%
for three-drug therapy), compared to individual bron-
chodilators (25% LABA or LAMA, 15% a combination
of two bronchodilators). It should be noted, however,
that one quarter of GPs opt for bronchodilator mono-
therapy even in patients at high risk of exacerbation
(Figure 9B).
As stated above, COPD patients tend to have a fairly high
level of comorbidity: heart failure, coronary artery disease,
diabetes, bone metabolism alterations, and depression;
weight loss, nutritional disorders, and skeletal muscle dys-
functions are also well recognized extra-pulmonary effects
of COPD [26-28]. This means that a multitasking treatment
may be required, i.e. a treatment aimed at different objec-
tives at the same time. In this regard, an important aspect is















































Figure 7 Top predictive factors of the risk of COPD exacerbation (max two options).
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portion of GPs and specialists (43% and 37% respectively)
opt for the fixed ICS + LABA combination, and a significant
proportion of specialists (35%) favours LAMAs.
As well known, a proportion of asthmatic patients
may evolve into clinical pictures related to COPD
[29-31], particularly if they are exposed to smoke or oc-
cupational dusts. Inadequate lung development at birth
may also make the respiratory tree more vulnerable to
external agents (e.g. smoke, viral infections), and be a
risk factor for early development of a scarcely reversible
obstruction process as well as of mixed or overlapping
forms of asthma and COPD. For these forms of overlap,
treatment of the underlying inflammation and reduction
of exacerbations were considered by both categories of
physicians as the primary objectives of therapy, along
with application of symptoms and general improvement
of patients’ quality of life (Figure 11).
Therapeutic continuity
Within the context of chronic disease like COPD, both
GPs and specialists consider therapeutic continuity to be
essential for all classes of drugs in order to achieve the
clinical outcomes (Figure 12).
Discussion
COPD prevalence data, in relation to a known chronic





Risk of hospital. GP (%) Spec. (%) GP (%) Spec. (%
Low 12,6 7,8 27,5 22,4
Medium 34,2 16 44,4 60,5
High 53,5 76 27,5 17disorder affects around 4-6% of the general population
[1], corresponding to approximately 3 million patients in
Italy. This figure almost certainly underestimates the real
size of the problem: in Italy, like in the rest of the world,
COPD is widely under-diagnosed, often goes untreated
until the advanced stages, and appears to be a major
issue even among young adult [32,33].
Against this backdrop, the results of the survey indi-
cate that a high percentage of GPs (approximately one
third of them identified more than 50 of their patients
with COPD), indicating an increased awareness of this
disease in Primary Health Care.
Hopefully, this will result in greater attention to alarm-
ing symptoms and greater use of diagnostic tools, which
would allow patients to be treated early on and to slow
down their evolution towards disability. On the other
hand, the fact that a significant percentage of GPs (44%)
diagnosed with COPD fewer than 20 patients (much
below all epidemiological data) suggests a need to con-
tinue to offer educational programs in this field. As it is
well known, COPD can go undetected for a long time,
because patients initially tend to minimize or ignore
symptoms like cough and increased phlegm, which they
may consider as a “normal” consequence of smoking,
and get used to the difficulties caused by the disease by
reducing their exercise. This is why they often first
present for examination in an advanced stage of the dis-
ease [34]. These considerations emphasize the strategichospitalization




) GP (%) Spec.(%) GP (%) Spec. (%)
27,5 30 83 80,8
56 46,5 15 16,4



































Figure 8 Indication of a pharmacological approach potentially effective for all COPD patients.
1 = not important 6 = very important
























Figure 9 Role of physiopathological mechanisms (A) and therapeutic approach (B) in COPD patients with frequent exacerbations.
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Figure 10 Therapeutic choices in patients with COPD and cardiovascular comorbidity.
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means, specific questionnaires administered to patients
at risk, such as smokers.
While a large majority of patients is or has been in
treatment with a long-acting bronchodilator, the most
common causes of the medical examination are exacer-
bations and worsening of the symptoms, both for GPs
and for specialists: this confirms the importance of an
appropriate background therapy in order to reduce the
risk of disease instability and use of healthcare resources
alongside with compliance to inhalation therapy. To
note, in patients with chronic bronchial obstructive dis-



















Figure 11 Therapeutic objectives in patients with asthma and a scarcand errors in the use of inhalators are very common
[35-40]: in this regard, physicians can play an essential
role in patient education on therapeutic adherence, in-
cluding the correct use of devices, thus improving dis-
ease management [41].
Virtually all physicians, both GPs and specialists, be-
lieve that there are different types or phenotypes of pa-
tients. The “frequent exacerbator” phenotype is one of
the most commonly seen both by GPs and specialists in
everyday clinical practice, with an estimated prevalence
of more than 30% of the COPD patient population ac-
cording to over one third of the physicians. The patient










ely reversible obstruction (max three options).





















Figure 12 Importance of therapeutic continuity.
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30% by approximately half of the physicians), while the
phenotype with prevalence of emphysema is more com-
monly reported by specialists. The fact that the type of
patients with significant reversibility to the bronchodila-
tion test is encountered rarely presumably reflects the
infrequent use of spirometry. It should be specified that
data recently emerged from the ECLIPSE study have
demonstrated that in many COPD patients reversibility
is not a stable characteristic, and therefore does not de-
fine a phenotype [42].
With regard to COPD staging, a medical history of ex-
acerbations and the extent of deterioration of spirometry
parameters are considered to be top indicators for
COPD severity. A primary role is attributed to disease
exacerbations particularly by specialists, in line with sci-
entific evidence which has conclusively demonstrated
that spirometry parameters alone (FEV1) do not reflect
the complexity of the disease and are insufficient to clas-
sify its severity [1]. In fact, the guidelines and recommen-
dation documents advocate a multidimensional patient
assessment, in which the measurement of bronchial ob-
struction is complemented with an evaluation of the risk
of exacerbations and the presence of comorbidities [1,25].
To note, the 2013 update of GOLD guide-lines indicate
that even one hospitalization for COPD exacerbation
should be considered high risk [1].
The frequent exacerbator phenotype is considered at
highest risk of hospitalization by both categories of phy-
sicians. Furthermore, knowing the frequency of exacer-
bations is viewed as essential to determine the clinical
risk: in this respect, it is interesting to note that mostspecialists – unlike GPs – indicate a clinical history of
exacerbations as the predictive factor most closely corre-
lated with their frequency, in line with the findings of
the ECLIPSE study [8] and with evidence from everyday
clinical practice. It is worth mentioning that a recent
study has demonstrated prospectively that COPD pa-
tients are able to estimate accurately the frequency of
the exacerbations they experienced during the previous
year [43]. The reliability and “strength” of their recollec-
tion allow the different types of patients – frequent
exacerbators and non-frequent exacerbators - to be
identified on the basis of medical history.
Another important aspect in assessing COPD patients’
clinical picture is the presence of comorbidities, particu-
larly of a cardiovascular nature, widely recognized both
by GPs and by specialists. The preliminary data of a
cross-sectional European study have demonstrated that
the prevalence of reduced air flow in a sample of 1,803
patients with cardiovascular disease treated on an out-
patient basis is 30.6%; interestingly, only 29.4% of these
had been previously diagnosed with COPD [44]. There-
fore, a reduced air flow compatible with COPD is com-
monly found and under-diagnosed in patients with
cardiovascular conditions. The presence of comorbidities
or complications is relevant in determining COPD evo-
lution and prognosis: it is estimated that approximately
50% of COPD patients die of cardiovascular causes, and
the risk of death and hospitalization is higher the more
severe the airway obstruction, regardless of whether the
patient is a smoker or a non-smoker [45,46].
While recognizing the existence of different types or
phenotypes of COPD patients, approximately half of the
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logical approach, which is effective for all patients. This
approach is a combination of inhaled corticosteroid and
bronchodilator, presumably because of the complemen-
tary pharmacological action of its components.
Taking therapeutic measures aimed at reducing the
number and severity of exacerbations clearly results in
savings in financial, social and health care resources
[17]. In the treatment of frequent exacerbators, both
GPs and specialists indicate reduction of airway inflam-
mation, bronchodilation and reduction of pulmonary
hyperinflation, which is responsible for low tolerance to
physical effort, as essential to achieve the therapeutic ef-
fect. Accordingly, for this type of patients at high clinical
risk, specialists sculpt primarily for regimens containing
inhaled corticosteroid in fixed combination with LABA
(or a three-drug therapy in combination with two bron-
chodilators), in line with evidence reported by literature
and incorporated into the guidelines, while GPs’ choices
tend to be more diversified, without a clear-cut preva-
lence of one type of treatment.
In patients with COPD and other concomitant disor-
ders, frequently of a cardiovascular nature, special atten-
tion should be given to treatment tolerability: a fixed
ICS + LABA combination is the first-line option accord-
ing to the highest proportion of GPs and specialists,
while a fairly large number of specialists opt for LAMAs.
It is worth recalling that long-term clinical studies con-
ducted on large populations of patients, many of whom
had cardiac disorders and were in treatment with anti-
arrhythmic agents, demonstrated a good tolerability pro-
file of the ICS + LABA combination, at cardiovascular
[47,48] as well as bone tissue level [49]; in general, the
same can be said of long-acting bronchodilators [48,50].
In the forms of asthma evolving towards permanent
obstruction, typical of patients who persist in the habit
of smoking, or in mixed or overlapping forms of asthma
and COPD, treatment of the underlying inflammation
and reduction of exacerbations are considered by both
categories of physicians as primary objectives of the
therapy. Interestingly, the PLATINO study, a multicen-
ter population-based survey carried out in five Latin
American cities, report that the COPD-Asthma overlap
is associated with increased severity, as indicated by the
higher risks for exacerbations and hospitalizations com-
pared to those with COPD [33].
Both GPs and specialists believe that therapeutic con-
tinuity is of the essence for the achievement of clinical out-
comes with all classes of drugs. The literature reports
examples of clinical worsening and failure to achieve thera-
peutic objectives due to low compliance with continuous
treatment. A post hoc analysis of the TORCH study dem-
onstrated that compliance is associated with a significant
reduction of the risk of death and hospitalization due toexacerbations in COPD patients, regardless of treatment
[51]. Another example is the observation that discontinu-
ation of inhaled corticosteroid in patients with moderate-
to-severe COPD stabilized with fluticasone/salmeterol
combination led to a fast and significant deterioration
of the function and symptoms and to increased exacer-
bations, confirming the role played by this class of
drugs in the background treatment of COPD [23,24].
Conclusions
In conclusion, a good knowledge and awareness of COPD
has been observed in a high percentage of GPs. The fre-
quent exacerbator phenotype is viewed by both specialists
and GPs as the most prevalent in clinical practice, bearing
a high risk of hospitalization. For specialists, therapeutic
measures aimed at reducing the number and severity of
exacerbations are primarily based on the combination of
inhaled corticosteroid and bronchodilator, presumably be-
cause of the complementary pharmacological action of its
components, whereas while GPs’ choices tend to be more
diversified. Adherence to medication regimens is of the es-
sence for the achievement of clinical outcomes.
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